Aprea - APRE Enterprise Value-to-Sales Ratio

Official company branding of Aprea Therapeutics Inc. (APRE)

Aprea Therapeutics focuses on developing targeted therapies to combat solid tumors by advancing its R&D cycle. The business's financial foundation relies on grants and successful clinical trials. Patent protection minimizes dumping, although risks persist due to competition from Big Pharma. The current level of 0.00 indicates the parameter's status, while the EV/Sales multiple on the GURU.Markets chart demonstrates the company's adaptation to borrowing costs.

Aprea Therapeutics, Inc. (APRE): Company Value to Revenue from 11/23/2025 to 11/20/2026

Aprea Therapeutics, Inc. - analytical breakdowns and key metrics (APRE)

- price and consensus price forecast:
Fundamental company valuation:APRE, Aprea
Manufactured products of aprea.com

This indicator measures the total business value relative to generated revenue, excluding the impact of debt load to identify capitalization overheating. By analyzing the current enterprise value-to-revenue ratio, an investor can assess the risk of a price correction amid the diversification of Aprea Therapeutics (APRE) into solid tumors and hematology segments, which potentially justifies a high market premium for the development of p53 protein therapy.